首页> 外国专利> METHOD FOR COMBINED TREATMENT OF LOCALLY ADVANCED FORMS OF CERVICAL CANCER IIB-IIIB (T2B-T3BN0(1)M0) STAGES

METHOD FOR COMBINED TREATMENT OF LOCALLY ADVANCED FORMS OF CERVICAL CANCER IIB-IIIB (T2B-T3BN0(1)M0) STAGES

机译:组合治疗宫颈癌IIB-IIIB(T2B-T3BN0(1)M0)阶段的局部晚期形式的方法

摘要

FIELD: pharmaceuticals. ;SUBSTANCE: invention relates to the field of pharmaceuticals, namely to a method for combined treatment of locally advanced forms of cervical cancer IIB-IIIB (T2b-T3bN0(1)M0) stages. The method includes the first stage of treatment, during which 2 courses of neoadjuvant polychemotherapy are carried out with an interval of 21 days: intravenous administration of paclitaxel and cisplatin in certain doses in the form of a 3-hour infusion with previous premedication, as well as 30 minutes before the administration of paclitaxel, intramuscular administration of dexamethasone or intra-arterial administration of cisplatin at a certain dose, alternately in the right and left uterine arteries and the next day, intravenous administration of paclitaxel is performed in the form of a 3-hour infusion with previous premedication, as well as 30 minutes before the administration of paclitaxel intramuscular administration of dexamethasone, 21 days after the last course of chemotherapy, combined chemoradiation therapy is carried out: distance - 3D conformal radiation therapy or intensity-modulated radiation therapy (IMRT), or volumetric modulated arc therapy - VMAT of the small pelvis and areas of regional metastasis. The total boost dose is 46-50 Gy. The fractionation mode is 2 Gy daily 5 times per week. Moreover, during remote irradiation as a radiomodification - cisplatin is administered at a certain dose, at 4-5 weeks of irradiation on days free from remote irradiation, brachytherapy is performed in 4 fractions of 7 Gy to the total boost dose equivalent of 30 Gy, total doses from the course combined radiation therapy are: in t. A 80-90 Gy, in t. B 60 Gy, and the volume of irradiation directly includes the primary tumor, the parametric region, sacro-uterine ligaments, the optimal distance from the edge of the primary tumor is not less than 3 cm, taking into account the level of tumor lesions of the vagina, the group of pelvic lymph nodes, as well as all other regional lymph nodes.;EFFECT: invention improves efficiency of treatment of patients with locally advanced cervical cancer by increasing the overall and disease-free survival rates, as well as improving the quality of life.;1 cl, 2 ex
机译:领域:药品。物质:本发明涉及药物领域,即用于组合治疗局部晚期宫颈癌IIB-IIIB-IIIB-IIIB-IIIB(T2B-T3BN0(1)M0)阶段的方法。该方法包括第一阶段的治疗阶段,在此期间,每种疗程的新辅助聚氯胺疗法进行21天的间隔:静脉内施用紫杉醇和顺铂,以3小时输注的形式,以及先前的预期在紫杉醇给予紫杉醇前30分钟,肌肉内施用地塞米松或动脉内施用顺铂在某种剂量,交替地在右侧和左子宫动脉和第二天,静脉施用紫杉醇以3的形式进行紫杉醇。 -Hour incusion与先前的预生,以及在帕希特克西克斯诊所给药前30分钟的地塞米松,在最后一夜化疗后21天进行,组合化学疗法:距离 - 3D保形放射治疗或强度调制的放射治疗(IMRT),或体积调制电弧疗法 - 小骨盆的VMAT和区域转移的领域。总增压剂量为46-50倍。分馏模式每周每天为2 Gy 5次。此外,在远程辐射期间,作为辐射缺陷的辐射 - 顺铂在某种剂量上施用,在4-5周的辐照上,从远程照射的日子,在7种级数的4分部分下进行近距离升压剂量等同于30 Gy的总增压剂量,来自课程的总剂量结合放射治疗是:IN T.一个80-90 gy,在t。 B 60 gy,并且辐射体积直接包括原发性肿瘤,参数区域,骶胞嘧啶韧带,从原发性肿瘤边缘的最佳距离不小于3cm,考虑到肿瘤病变的水平阴道,盆腔淋巴结组,以及所有其他区域淋巴结。;效果:通过增加整体和无病的生存率以及改善局部和疾病的生存率来提高局部晚期宫颈癌患者的治疗效率,以及改善生活质量。; 1 cl,2前

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号